Joel Greenblatt's TGTX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 44,905 shares of TG Therapeutics, Inc. (TGTX) worth $2.47 M, representing 0.01% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2022, adding 126,442 shares. Largest reduction occurred in Q4 2024, reducing 64,333 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -266 | Reduce 0.59% | 44,905 | $54.94 |
| Q1 2026 | -10 | Reduce 0.02% | 45,171 | $33.22 |
| Q4 2025 | -151 | Reduce 0.33% | 45,181 | $29.81 |
| Q2 2025 | -1,403 | Reduce 3.00% | 45,332 | $35.99 |
| Q1 2025 | -4,214 | Reduce 8.27% | 46,735 | $39.43 |
| Q4 2024 | -64,333 | Reduce 55.80% | 50,949 | $30.10 |
| Q3 2024 | +41,975 | Add 57.26% | 115,282 | $23.39 |
| Q2 2024 | +1,731 | Add 2.42% | 73,307 | $17.79 |
| Q1 2024 | -24,674 | Reduce 25.64% | 71,576 | $15.21 |
| Q4 2023 | +24,827 | Add 34.76% | 96,250 | $17.08 |
| Q3 2023 | -59,271 | Reduce 45.35% | 71,423 | $8.36 |
| Q2 2023 | +9,807 | Add 8.11% | 130,694 | $24.84 |
| Q1 2023 | -5,555 | Reduce 4.39% | 120,887 | $15.04 |
| Q4 2022 | +126,442 | New Buy | 126,442 | $11.83 |
| Q2 2021 | -10,756 | Sold Out | 0 | $0.00 |
| Q1 2021 | -22,960 | Reduce 68.10% | 10,756 | $48.16 |
| Q4 2020 | +16 | Add 0.05% | 33,716 | $52.02 |
| Q3 2020 | -11,088 | Reduce 24.76% | 33,700 | $26.77 |
| Q2 2020 | +44,788 | New Buy | 44,788 | $19.47 |
| Q4 2019 | -11,105 | Sold Out | 0 | $0.00 |
| Q3 2019 | +11,105 | New Buy | 11,105 | $5.58 |
Joel Greenblatt's TG Therapeutics Investment FAQs
Joel Greenblatt first purchased TG Therapeutics, Inc. (TGTX) in Q3 2019, acquiring 11,105 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held TG Therapeutics, Inc. (TGTX) for 22 quarters since Q3 2019.
Joel Greenblatt's largest addition to TG Therapeutics, Inc. (TGTX) was in Q4 2022, adding 126,442 shares worth $1.5 M.
According to the latest 13F filing for Q2 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 44,905 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $2.47 M.
As of the Q2 2026 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in TG Therapeutics, Inc. (TGTX) was 130,694 shares, as reported at the end of Q2 2023.